Amylyx Pharmaceuticals Inc logo

Amylyx Pharmaceuticals Inc

AMLX
Healthcare|Drug Manufacturers - Specialty & Generic|USA
$17.77
-0.60 (-3.29%)
Tangible Book
$2.46

Upcoming Data Readouts (1)

Feb 2027
Est. completion
P1ALS
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165n=48

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Mar 2026
P3
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468
Jul 2024
P2
AMX0035 in Adult Patients With Wolfram Syndrome
NCT05676034
Jan 2024
P3
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
NCT05021536

Recent Press Releases